Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619191 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1403984 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL3207354 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404048 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL30980916 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404082 | 1.00 | HRH3 (0.70) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404107 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL11859421 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL1404023 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL9158672 | 0.97 | HRH3 (0.75) | HRH3MAPTCYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| CN-100349851-C | Method for producing acrylic acid esters | BASF AG (DE) | 2007-11-21 | — | — | CN | claimed |
| CN-100349854-C | Method for producing (meth) acrylic acid esters | BASF AG (DE) | 2007-11-21 | — | — | CN | claimed |
| US-7026503-B2 | Method for producing (meth)acrylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | claimed |
| EP-1399408-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AG (DE) | 2006-03-22 | — | — | EP | claimed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-115385892-A | Desloratadine derivative, preparation method and application thereof | 天津市昕晨投资发展有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-10174349-B2 | Recombinant cell producing 2-hydroxyisobutyric acid | EVONIK ROEHM GMBH (DE) | 2019-01-08 | — | — | US | disclosed |
| EP-2291530-B1 | RECOMBINANT CELL PRODUCING 2-HYDROXYISOBUTYRIC ACID | EVONIK ROEHM GMBH (DE) | 2018-12-26 | — | — | EP | disclosed |
| CN-101186568-A | Process for preparing (meth)acrylic acid | EVONIK ROEHM GMBH (DE) | 2008-05-28 | — | — | CN | disclosed |
| CN-101186603-A | Process for preparing tetramethyl glycolide | EVONIK ROEHM GMBH (DE) | 2008-05-28 | — | — | CN | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-0382213-B1 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMA CO LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-5053548-A | Containing hydroxy substituents; nervous system disorders | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0382213-A2 | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0289262-A2 | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-11-02 | — | — | EP | disclosed |
| US-4455168-A | CONTAINING A HETEROCYCLIC, HYDROXY AMINE OR AMIDE | RICOH COMPANY, LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | HRH3 538/4885MAPT 4299/4885CYP1A2 420/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | HRH3 2171/4885MAPT 4029/4885CYP1A2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.